We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Now that he has more extensive metastases and he has already had a nephrectomy and resection of a previous lung lesion and progressing on systemic therapy, in my opinion cytoreductive surgery would not be considered an option. Radiation therapy to the acromial metastasis may be reasonable for pain control (even though radiation is not the optimal modality in RCC).
Thanks Dr. Richey - I agree. Also, what would be a good choice for second line therapy in this case and how does first line therapy affect the choice of agent used in treating at progression?
As he has already received treatment with a VEGF TKI, now an mTOR inhibitor like everolimus may be a good option for second line therapy. In the RECORD 1 Trial, everolimus was used compared to placebo for patients with metastatic RCC who progressed on sunitinib or sorafenib , the primary end point was progression free survival that was significantly prolonged in the everolimus arm ( 4 vs. 1.9 months) Another good option would be axitinib (NCCN Category 1).
Wolfgang Lilleby
Aug 20, 2014
Dear doctior Pandey, efficient radiotherapy depends on the size of the lesions and fraction, so radiotherapy giving stereotactically could be still an option.
Sanjay Bangroo
Aug 20, 2014
mTOR inhibitor like Everolimus could be a good option.....however counter weightage needs to be given to patients hypertensive and diabetic status. Axitinib might be worth thinking about
Nick Antoniou
Aug 20, 2014
A second line therapy with everolimus would be an appropriate choice for this patient although I don't believe it helps much.same as the old interleukin some partial response.thank you very much.
Comment deleted by Moderator.
Peggy Zuckerman
Aug 20, 2014
Rather than considering just additional surgery, would there not be a role for high-dose interleukin, given his general health status, age and limited response to sunitinb? Perhaps ablation to the largest mets should precede the IL2.
YL3DB40N2X52587 YL3DB40N2X52587
Aug 20, 2014
A metastasectomy would result in cytoreduction. But whether it improves survival - that is a question that has not yet been adequately studied. A few studies have shown that metastasectomy does improve survival in some patients with advanced renal cell carcinoma. At this point, we still do not have enough information to rule out the benefit of cytoreductive surgery, even in the situation above.
franco morelli
Aug 24, 2014
In my opinion cytoreductive surgery would not be considered an option. A good chance for second line therapy in this case may be axitinib.
Comment deleted by Moderator.
Sandro Cavallero
Aug 26, 2014
I agree that Axitinib could be a good choice, but it isn`t approved in Brazil. In this case i'll choose Sorafenib or Everolimus. The Switch trial show us that we can use another VEGFR TKI in second line, and in March 10, Hwang and Heath published at JCO "The judgment of Paris", and there they suggest that patients who used VEGF inhibitor for more than 6m, could use another VEGFR TKI. In this case I'll use Sorafenib in second line. In my opinion cytoreductive surgery would not be considered an option.
Dr. Lilleby: With his age (55yrs), comorbidities (HTN/DM) I would be hesitant to use IL2. Further with the availability of the newer agents TKIs, mTOR inhibitors the role of IL2 is less clear, especially in this setting.
Dr. Cavallero: That is a good thought, one could consider switching to sorafenib per the results of the SWITCH trial. And now we also have the results of the RECORD-3 trial to guide us, that compared the use of everolimus followed by sunitinib to sunitinib first and then everolimus. This study failed to show non-inferiority of the everolimus followed by sunitinib approach. Basically saying that most likely starting with sunitinib first and switching to everolimus only in the second-line, is the right choice.
erich lang
Aug 27, 2014
Sorafenib in second line may be the best option
92TW5N19JA75933 92TW5N19JA75933
Sep 13, 2014
I think Axitinib the best choice - cytoreductive surgery would not be considered an option and not increases OS - Radiation therapy for pain control
Neil Halin
Nov 28, 2014
If his acromial lesion is his most symptomatic site, why not consider local ablation of the lesion with cemetoplasty. In this instance either cryo- or heat (pick your modality) could be utilized.
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Sylvia Richey MD
Jul 03, 2014
Manjari Pandey MD
Jul 03, 2014
Bradley G. Somer MD
Jul 03, 2014
Wolfgang Lilleby
Aug 20, 2014
Sanjay Bangroo
Aug 20, 2014
Nick Antoniou
Aug 20, 2014
Peggy Zuckerman
Aug 20, 2014
YL3DB40N2X52587 YL3DB40N2X52587
Aug 20, 2014
franco morelli
Aug 24, 2014
Sandro Cavallero
Aug 26, 2014
Manjari Pandey MD
Aug 27, 2014
Manjari Pandey MD
Aug 27, 2014
Manjari Pandey MD
Aug 27, 2014
Manjari Pandey MD
Aug 27, 2014
erich lang
Aug 27, 2014
92TW5N19JA75933 92TW5N19JA75933
Sep 13, 2014
Neil Halin
Nov 28, 2014
Apr 19, 2024
Pending Moderator approval.